First Quarter 2012 Financial Results Conference Call May 3, 2012 - - PowerPoint PPT Presentation

first quarter 2012
SMART_READER_LITE
LIVE PREVIEW

First Quarter 2012 Financial Results Conference Call May 3, 2012 - - PowerPoint PPT Presentation

First Quarter 2012 Financial Results Conference Call May 3, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to,


slide-1
SLIDE 1

First Quarter 2012 Financial Results Conference Call

May 3, 2012

slide-2
SLIDE 2

1

Forward-looking Statements

Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding the closing of pending transactions, expected revenue and synergies, product approvals and launches and financial guidance for 2012. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,”

  • r “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs
  • f management and are subject to certain risks and uncertainties that could cause actual results to differ materially from

those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, stock- based compensation step-up, restructuring and acquisition-related costsTBD, acquired in-process research and development ("IPR&D"), legal settlements, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, and (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core

  • perating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with

GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Note 1: The guidance in this presentation is only effective as of the date given, May 3, 2012, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.

slide-3
SLIDE 3

2

Agenda

  • 1. First Quarter Results
  • 2. Emerging Market Overview
  • 3. Specialty Pharmaceuticals Update
  • 4. Finance Update
  • 5. 2012 Guidance Update
slide-4
SLIDE 4

3

Strong 1Q Earnings and Cash Generation Performance

Q1 2011* Q1 2012* Q1 2012 vs 2011 Product Sales $500 M $768 M 54% Cash EPS $0.56 $0.99 77% Adjusted Cash Flow $204 M $255 M 25%

*First quarter 2011 excludes $36 M from the out-license of Cloderm and first quarter of 2012 excludes $66 M from divestiture of

IDP-111 and generic Efudex

slide-5
SLIDE 5

4

Strong Organic Growth

Organic Growth

24%

  • 10%

22% 12%

First Quarter 2012

Emerging Markets Canada/ Australia U.S Neurology & Other U.S Dermatology

Total Company Organic Growth 11%

slide-6
SLIDE 6

5

Deal Update

Announced YTD 2012

 Probiotica (Brazil) – Closed  EyeTech (U.S.) – Closed  Pele Nova (Brazil) – Closed  Pedinol (U.S.) – Closed  Natur Produkt (Russia) – (Expected to Close mid-year)  Gerot Lannach (Russia) – Closed  Atlantis (Mexico) – (Expected to Close 2Q12)  AcneFree (U.S.) – (Expected to Close mid-year)

Other transactions

 Divested Bioskin  Acquired assets - Ortho Dermatologics – Canada  Acquired assets – Ortho Dermatologics - Brazil

Total Purchase Price = ~$600 million Expected 2012 Revenue Run Rate = ~$280 million Sales Multiple Paid = ~2.1 X

slide-7
SLIDE 7

6

Progress on 2012 Synergy Program

Run rate expected by mid-year Run Rate

May 3, 2012

$200 million $165 million

Run Rate

Feb 23, 2012

$135 million

Run rate expected by Year-end

$230+ million*

* Includes acquisitions announced and closed in 2012

slide-8
SLIDE 8

7

Emerging Markets

Total Run Rate

(After deals closed)

Brazil Mexico Latin America All Other Serbia Russia Central/Eastern Europe Poland South Africa Thailand Malaysia Philippines South East Asia/South Africa Export Asia - Other

Additional Updates:

  • Europe – 76 new launches year-to-date
  • Brazil – Regederm launched in April

>$1.2 billion

~$350M ~$100M ~$750M

slide-9
SLIDE 9

Specialty Pharmaceuticals Update

slide-10
SLIDE 10

9

US Neurology Performance

Q1 2012 Net Sales Q1 2012 vs. Q1 2011

Wellbutrin XL Cardizem CD Ultram ER Core Neuro & Other

Total

All Other Wellbutrin XL Cardizem CD Ultram ER Total

$48M $135M $183M

6% (10)% (37)%

slide-11
SLIDE 11

10

Strong Continued Performance on Key Dermatology Growth Assets

2012 vs. 2011 Volume Growth (MAT)

Source: Wolters Kluwer Health; IRI Scan data; Retailer data 37% 38% 28% 12%

0% 10% 20% 30% 40% 50% 60% 70% Acanya* Atralin Zovirax** CeraVe***

*Acanya impacted by unusually high March 2011 TRx volume **Zovirax volume in TRx grams ***CeraVe scan volume growth

slide-12
SLIDE 12

11

Strong Dermatology Brand Performance Despite Weak Market Growth in March

Source: Wolters Kluwer Health

Market Growth 2012 vs. 2011 Q1 2012 March 2012 Topical Calcineurin Inhibitors (Derm only) – e.g., Elidel 6.9% (0.2%) Fixed Dose Acne Combo (BPO / Clindamycin) – e.g., Acanya (4.5%) (10.6%) Tretinoins – e.g., Atralin 5.6% (3.9%) Anti-Viral – e.g., Zovirax 3.9% (0.4%)

slide-13
SLIDE 13

12

Other Portfolio Updates

 Canada

 Product Launches

 Lodalis; Sublinox

 Generic competition for Cesamet

 U.S. Neuro & Other

 Potiga U.S. launch

 U.S. Dermatology

 IDP-108 Update

slide-14
SLIDE 14

Financial Update

Howard Schiller

slide-15
SLIDE 15

14

Financial Summary

Q1 2011* Q2 2011 Q3 2011 Q4 2011 Q1 2012* Product Sales $500M $530M $570M $654M $790M Total Revenue $565M $609M $601M $688M $856M Cost of Goods Sold% 27% 29% 28% 25% 26% SGA% 21% 22% 21% 21% 19% R&D Expense $14M $18M $18M $17M $22M Operating Margin 50% 53% 50% 57% 55% (excluding amortization) Cash EPS $0.62 $0.73 $0.66 $0.94 $1.14 Adjusted Cash Flow from Operations $204M $260M $208M $253M $322M Fully Diluted Share Count 333 M 331 M 323 M 317 M 316 M

* Includes out-licensce of Cloderm in Q1’11 and divestiture of dermatology products in Q2’12

slide-16
SLIDE 16

15

Revenue by Segment Q1 2012 vs Q1 2011

38% 27% 12% 23%

Neuro Derm Canada / Australia Emerging Markets

U.S. ~52% U.S. ~65%

Q1 2011 Q1 2012

24% 28% 17% 31%

slide-17
SLIDE 17

16

Cost of Goods Sold (COGS)*

Sequential increase due to:

Increased Canada contract manufacturing

Product Mix (U.S. & Europe)

Unfavorable Exchange Rates (Europe)

Delayed plant consolidations

* COGS based on product sales only

Q4’11 Q1’12 U.S. Neuro 17% 18% U.S. Derm 11% 10% Can/Aus 23% 26% Emerg Mkts 42% 47% Total COGS 25% 26%

slide-18
SLIDE 18

17

Q1’12 Cash Flow

$164 $322 $350 $113 $302 $11 $87 $8 $330

Cash December 2011 Securities Repurchases Acquisitions Cap Ex Restructuring/ Integration/ Legal Settlements Other2 Cash March 2012 Net Issuance LT Debt Adjusted CashFlow from Operations1

2Includes payment of withholding tax upon vesting of share based awards, one-time working capital adjustments, proceeds from the

exercise of stock options and other miscellaneous cash outflows

1Includes impact of divestiture of IDP-111 and 5FU

slide-19
SLIDE 19

18

Financial Updates

 FX Impact

 Resulted in a ~$20 million reduction to revenue

 Working Capital Improvement

 Improved from 35% of LTM revenue in Q4 11 to 30% of LTM revenue in Q1 12  Inventory increased vs Q4 due to stock build related to tech transfers (Brazil,

U.S.)

 Securities Repurchase Program

 Repurchased over 2 million common shares for an aggregate purchase

price of $108.7 million

 316 million fully diluted share count as of March 31, 2012

Currency Poland Serbia Hungary Russia Australia Canada Mexico Brazil South Africa Q1’11 vs Q1’12

  • 11%
  • 8%
  • 12%
  • 3%

5%

  • 2%
  • 7%
  • 6%
  • 10%
slide-20
SLIDE 20

2012 Guidance

  • J. Michael Pearson
slide-21
SLIDE 21

20

Annual Financial Guidance for 2012

Previous Guidance

Revenue $3.1 - $3.4 billion

$3.95 - $4.20 Adjusted Cash EPS

> $1.2 billion in Adjusted Cash Flow from Operations

As of May 3, 2012

Revenue > $3.4 - 3.6 billion

$4.45 - $4.70 Adjusted Cash EPS

> $1.4 billion in Adjusted Cash Flow from Operations

See Note 1 regarding guidance

slide-22
SLIDE 22

First Quarter 2012 Financial Results Conference Call

May 3, 2012